Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus ACTICLATE CAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus ACTICLATE CAP.
ACHROMYCIN vs ACTICLATE CAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic